Preclinical And Translational Vaccine Development For HIV And Other Candidate Agents

The National Institute of Allergy and Infectious Diseases (NIAID) established a Master IDIQ on December 1, 2021 to procure preclinical and translational vaccine development services for HIV and other candidate agents, with ordering authority extending through November 30, 2028—approximately two years and four months of remaining opportunity.

The vehicle serves a narrowly focused mission: preclinical support activities spanning product storage and shipping, safety and immunogenicity studies, feasibility assessments, analytical development, process development, CGMP manufacturing, stability testing, fill-finish operations, and scientific and quality support. Awarded task orders confirm this scope; recent orders include feasibility studies for liposome and lipid nanoparticle HIV envelope trimer vaccines, GLP toxicology studies for adjuvanted candidates, and CGMP manufacturing with fill-finish and stability testing for mRNA and nanoparticle-based HIV immunogens. Base period performance runs June 2021 through June 2028.

Duke University dominates the vehicle, holding 3 of 9 task orders with a combined potential value of $20.2 million—approximately half of the vehicle's $40.1 million combined potential value. The International AIDS Vaccine Initiative holds $8.4 million across one order; Advanced Bioscience Laboratories (a predecessor single-award incumbent) holds $3.8 million across two orders. The remaining three primes—Technical Resources International, MRI Global, and one other—share the balance. All nine task orders carry no set-aside designation and obligate a combined $30.1 million against the $40.1 million potential, indicating 75% of committed value already locked down. All orders fund NIAID directly; no other agencies place orders under this vehicle.

Task orders range from small minimum-guarantee orders ($2,500) to mid-sized development awards of $5.9 million to $10.4 million ceiling. Completion dates span through August 2030. Ordering momentum has been episodic—five orders in 2021, one in 2023, and three in 2024—suggesting unpredictable but active demand within the vehicle's remaining 28-month window.

The development of a safe and efficacious preventive HIV-1 vaccine is one of the highest priorities of the National Institute of Allergy and Infectious Diseases (NIAID). NIAID supports a portfolio of preclinical, translational, and clinical research to advance HIV vaccine efforts. The Division of AIDS (DAIDS) supports research programs to discover novel vaccine strategies, assess correlates of immunogenicity and of protections elicited by experimental vaccines and provides an infrastructure for the manufacturing and testing of novel products.